- Home
- MCHP vs ONC Comparison
MCHP vs ONC Comparison
Compare MCHP & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCHP | ONC |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3B | 34.8B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | MCHP | ONC |
|---|---|---|
| Price | $78.58 | $345.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 12 |
| Target Price | $85.59 | ★ $370.25 |
| AVG Volume (30 Days) | ★ 10.9M | 231.8K |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | $4,372,400,000.00 | ★ $4,972,687,000.00 |
| Revenue This Year | $7.35 | $895.40 |
| Revenue Next Year | $19.75 | $22.04 |
| P/E Ratio | ★ N/A | $558.65 |
| Revenue Growth | N/A | ★ 50.43 |
| 52 Week Low | $34.13 | $196.45 |
| 52 Week High | $83.35 | $385.22 |
Technical Indicators
Market Signals| Indicator | MCHP | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 53.28 |
| Support Level | $73.50 | $342.00 |
| Resistance Level | $83.35 | $358.38 |
| Average True Range (ATR) | 3.24 | 9.89 |
| MACD | -0.23 | -0.64 |
| Stochastic Oscillator | 51.37 | 58.23 |
Price Performance
Historical ComparisonAbout MCHP Microchip Technology Incorporated
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.